Mi Zhou is an associate in the Litigation practice of Paul Hastings and is based in the firm’s New York office. Her practice focuses on complex patent litigation, with an emphasis on pharmaceuticals and biotechnology. She also has experience in patent prosecution and post-grant proceedings.
- University of Florida, Levin College of Law, J.D. (cum laude)
- State University of New York at Stony Brook, B.S. in Biochemistry (summa cum laude)
Actelion Pharmaceuticals Ltd et al. v. Zydus Worldwide DMCC et al.
- Represented Actelion, a Johnson & Johnson company, and Nippon Shinyaku in a patent infringement litigation against Zydus related to Uptravi®, an innovative drug for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization. Before litigating into expert discovery, Zydus admitted infringement and patent validity in consent judgments.
Actelion Pharmaceuticals Ltd v. Zydus Pharmaceuticals (USA) et al.
- Represented Actelion, a Johnson & Johnson company, in a patent infringement litigation related to Opsumit®, an innovative drug for the treatment of pulmonary arterial hypertension to reduce the risks of disease progression and hospitalization. The generic manufacturer defendants admitted infringement and patent validity in consent judgments.
Adamas Pharma LLC v. Sandoz, Inc.
- Represented Adamas in a patent infringement litigation related to Gocovri®, an innovative drug for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. After litigating into claim construction briefing, Adamas obtained a favorable settlement.
Arena Pharmaceuticals Inc. et al. v. Lupin Ltd. et al.
- Represented Eisai and Arena in a patent infringement litigation related to Belviq®, an innovative drug for the treatment of weight loss. The case settled with the generic manufacturer defendants stipulating to patent infringement.
Sumitomo Dainippon Pharma Co. Ltd. et al. v. Emcure Pharmaceuticals Ltd. et al.
- Represented Sumitomo Dainippon and Sunovion in a patent infringement litigation in the district court and the Federal Circuit related to Latuda®, a blockbuster drug for the treatment of schizophrenia and bipolar depression. After the district court’s claim construction decision that was favorable to Sumitomo Dainippon and Sunovion, the generic manufacturer defendants admitted infringement and patent validity in consent judgments. The Federal Circuit affirmed the district court’s claim construction decision and consent judgments.
Sanofi-Aventis US LLC et al. v. Eli Lilly & Co.
- Represented Eli Lilly in a patent litigation involving Eli Lilly’s request to market its insulin glargine drug product Basaglar®. The case settled on the eve of trial with the press reporting Eli Lilly’s ability to launch Basaglar® the following year.
- Takeaways from Recent Implementation of China’s Patent Linkage System - September 7th, 2021
- Considerations for Innovator Drug Companies Regarding China’s Drug Patent Linkage System - 中国将施行药品专利链接制度——创新药企应如何应变 - December 1st, 2020
- Takeaways from China’s Proposed Regulation to Implement a Drug Patent Linkage System - October 5th, 2020
- China’s Proposals to Provide a Patent Linkage System and Patent Term Extensions – Considerations for Drug Companies - July 27th, 2020
- What Drug Companies Should Be Thinking About After the U.S. - China Trade Deal - January 23rd, 2020
- How to Think About and Successfully Navigate Patent Eligibility After Alice, Myriad, and Mayo - December 17th, 2019
- Takeaways from Federal Circuit’s Decision in UCB v. Accord on Obviousness of Chemical Compounds - June 4th, 2018
- Federal Circuit Provides Additional Guidance for Induced Infringement in Hatch-Waxman Cases - November 13th, 2017